In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.
Underrepresentation of Black patients with psoriasis in trials and textbooks might partially explain why clinicians are slow to recognize nail involvement, even after psoriasis has been diagnosed.